Zobrazeno 1 - 10
of 169
pro vyhledávání: '"Wilhelm Mueller"'
Autor:
Farastuk Bozorgmehr, Inn Chung, Petros Christopoulos, Johannes Krisam, Marc A. Schneider, Lena Brückner, Daniel Wilhelm Mueller, Michael Thomas, Stefan Rieken
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/5127c969646443f1add3597e420188ff
Autor:
Farastuk Bozorgmehr, Inn Chung, Petros Christopoulos, Johannes Krisam, Marc A. Schneider, Lena Brückner, Daniel Wilhelm Mueller, Michael Thomas, Stefan Rieken
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background Non-small cell lung cancer is the most common cause of cancer death worldwide, highlighting the need for novel therapeutic concepts. In particular, there is still a lack of treatment strategies for the group of elderly and frail p
Externí odkaz:
https://doaj.org/article/6ee57f5784934692abfb91344ca3fbd7
Autor:
Lena Brückner, Mike Thomas, Marc A. Schneider, Inn Chung, Johannes Krisam, Farastuk Bozorgmehr, Stefan Rieken, Petros Christopoulos, Daniel Wilhelm Mueller
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer
BMC Cancer
Background Non-small cell lung cancer is the most common cause of cancer death worldwide, highlighting the need for novel therapeutic concepts. In particular, there is still a lack of treatment strategies for the group of elderly and frail patients,
Autor:
Daniel Wilhelm Mueller, Mike Thomas, Regina Eickhoff, Lena Brückner, Inn Chung, Albrecht Stenzinger, Marc A. Schneider, Farastuk Bozorgmehr, Johannes Krisam, Petros Christopoulos
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Background Availability of potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) has pushed the median survival of ALK+ non-smallcell lung cancer (NSCLC) patients to over five years. In particular, second-generation ALK TKI have de
Autor:
Bernd Kasper, Daniel Pink, Daniel Wilhelm Mueller, Martin Kortüm, Eva Wardelmann, Alexander Golf, Salah-Eddin Al-Batran, Anne Flörcken, Stephan Richter, Jeanette Bahr, Torsten Kessler, Dimosthenis Andreou, Disorn Sookthai, Peter Reichardt, Christian Schmidt
Publikováno v:
Journal of Clinical Oncology. 39:11545-11545
11545 Background: Single-agent PD-1 inhibitors have modest activity in the treatment of most STS. Potential strategies to increase efficacy include combination therapies targeting the tumor microenvironment. Considering that apart from direct growth
Autor:
Daniel Wilhelm Mueller, Elke Jäger, Mohammad-Reza Rafiyan, Dragan Kiselicki, Regina Eickhoff, Timursah Habibzade, Marina Schaaf, Thorsten Oliver Goetze, Salah-Eddin Al-Batran
Publikováno v:
Journal of Clinical Oncology. 39:2518-2518
2518 Background: Stratum D of the INSIGHT platform trial evaluates s.c. eftilagimod alpha (efti, IMP321) combined with avelumab in advanced solid tumors. Efti is an MHC class II agonist which activates antigen-presenting cells followed by CD8 T-cell
Autor:
Michael Geißler, Enrico N. De Toni, Gabriele Margareta Siegler, Andreas Teufel, Daniel Wilhelm Mueller, Tobias Müller, Oliver Waidmann, Matthias Kleiß, Angelika M. R. Kestler, Jens U. Marquardt, Guido Hausner, Salah-Eddin Al-Batran, Arndt Vogel, Ludwig Fischer von Weikersthal, Thorsten Oliver Goetze, Regina Eickhoff, Maria A. Gonzalez-Carmona
Publikováno v:
Journal of Clinical Oncology. 39:TPS4159-TPS4159
TPS4159 Background: The investigator-initiated IMMULAB study investigates the clinical activity of peri-interventional treatment with the anti-PD1 antibody pembrolizumab in HCC patients who are candidates for local ablation via either radiofrequency
Publikováno v:
J Vis Exp
3D bioprinting aims to create custom scaffolds that are biologically active and accommodate the desired size and geometry. A thermoplastic backbone can provide mechanical stability similar to native tissue while biologic agents offer compositional cu
Autor:
Salah-Eddin Al-Batran, U. Lindig, Daniel Wilhelm Mueller, Enrico N. De Toni, Jürgen Siebler, Gabriele Margareta Siegler, Martin Walker, Arndt Vogel
Publikováno v:
Web of Science
e16601 Background: Immuno-oncology (I-O) drug nivolumab binds to T-cell PD-1 receptor and overcomes tumor induced inhibition of T-cell proliferation and cytokine release caused by PD-L1/L2 interaction. It so enhances the immune system’s natural tum